The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Targeting Glutamine Metabolism and Redox State for Leukemia Therapy
Open accessAbstract
Purpose: Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the accumulation of immature myeloid precursor cells. AML is poorly responsive to conventional chemotherapy and a diagnosis of AML is usually fatal. More effective and less toxic forms of therapy are desperately needed. AML cells are known to be highly dependent on the amino acid glutamine for their survival. These studies were directed at determining the effects of glutaminase inhibition on metabolism in AML and identifying general weaknesses that can be exploited therapeutically. Experimental Design: AML cancer cell lines, primary AML cells, and mouse models of AML and acute lymphoblastic leukemia (ALL) were utilized. Results: We show that blocking glutamine metabolism through the use of a glutaminase inhibitor (CB-839) significantly impairs antioxidant glutathione production in multiple types of AML, resulting in accretion of mitochondrial reactive oxygen species (mitoROS) and apoptotic cell death. Moreover, glutaminase inhibition makes AML cells susceptible to adjuvant drugs that further perturb mitochondrial redox state, such as arsenic trioxide (ATO) and homoharringtonine (HHT). Indeed, the combination of ATO or HHT with CB-839 exacerbates mitoROS and apoptosis, and leads to more complete cell death in AML cell lines, primary AML patient samples, and in vivo using mouse models of AML. In addition, these redox-targeted combination therapies are effective in eradicating ALL cells in vitro and in vivo. Conclusions: Targeting glutamine metabolism in combination with drugs that perturb mitochondrial redox state represents an effective and potentially widely applicable therapeutic strategy for treating multiple types of leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
Glutamine and cancer: cell biology, physiology, and clinical opportunities
Hensley, C. T., Wasti, A. T., & DeBerardinis, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69600 · Cited by 1,262 · cited 1×
“Glutamine metabolism contributes to energy production, macromolecular synthesis, and redox homeostasis, and is essential for survival of some cancer cells that have become addicted to glutamine (6, 25, 26).”
BackgroundPollyea, D. A., Stevens, B. M., Jones, C. L., Winters, A., Pei, S., Minhajuddin, M., D’Alessandro, A., Culp-Hill, R., Riemondy, K. A., Gillen, A. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0233-1 · Cited by 778 · cited 1×
“Certainly, venetoclax in combination with hypomethylating agents (HMA) has been shown to be effective at both eradicating AML LSCs (33, 34) and augmentingmitoROS and apoptosis induction compared with HMA alone (35).”
BackgroundSelf-citationInhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
Jones, C. L., Stevens, B. M., D'Alessandro, A., Reisz, J. A., Culp-Hill, R., Nemkov, T., Pei, S., Khan, N., Adane, B., Ye, H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.005 · Cited by 585
Self-citationRedox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities
Wondrak, G. T. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2541 · Cited by 462
Kung, H.-N., Marks, J. R., & Chi, J.-T. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002229 · Cited by 277
Cited by
Weng, H., Huang, F., Yu, Z., Chen, Z., Prince, E., Kang, Y., Zhou, K., Li, W., Hu, J., Fu, C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.004 · Cited by 336
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy
Yang, W.-H., Qiu, Y., Stamatatos, O., Janowitz, T., & Lukey, M. J. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2021.04.003 · Cited by 287
Amino Acid Depletion Therapies: Starving Cancer Cells to Death
Butler, M., van der Meer, L. T., & van Leeuwen, F. N. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2021.03.003 · Cited by 268
Glutaminases regulate glutathione and oxidative stress in cancer
Matés, J. M., Campos-Sandoval, J. A., de los Santos-Jiménez, J., & Márquez, J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02838-8 · Cited by 91
Di Marcantonio, D., Martinez, E., Kanefsky, J. S., Huhn, J. M., Gabbasov, R., Gupta, A., Krais, J. J., Peri, S., Tan, Y., Skorski, T., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.05.008 · Cited by 67
Metadata
- Authors
- Gregory, M. A., Nemkov, T., Park, H. J., Zaberezhnyy, V., Gehrke, S., Adane, B., Jordan, C. T., Hansen, K. C., D’Alessandro, A., & DeGregori, J.
- Venue
- Clinical Cancer Research
- Published
- 2019-07-01
- Volume
- 25
- Issue
- 13
- Pages
- 4079-4090
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2951399368
- Cited by
- 171
- References
- 13
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Glutamine Metabolism and Redox State for Leukemia Therapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-3223
- The paper
- Gregory, M. A., Nemkov, T., Park, H. J., Zaberezhnyy, V., Gehrke, S., Adane, B., Jordan, C. T., Hansen, K. C., D’Alessandro, A., & DeGregori, J. (2019). Targeting Glutamine Metabolism and Redox State for Leukemia Therapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-3223
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.